Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aequus Pharmaceuticals Inc V.AQS

Alternate Symbol(s):  AQSZF

Healthcare
Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.


TSXV:AQS - Post by User

Aequus Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1499)
•••
Post by Fishercat1on May 13, 2024 4:56pm
99 Views
Post# 36037566

Hum. Almost A Million Traded . 148,521 Average vol

Hum. Almost A Million Traded . 148,521 Average vol
V:AQS - Aequus Pharmaceuticals Inc. - https://www.aequuspharma.ca
Sym-X Bid - Ask Last Chg %Ch Vol $Vol #Tr Open-Hi-Lo Year Hi-Lo Last Tr News Delay
AQS - V   100.0 0.02 · 0.025 351.0 0.025 +0.005 25.0 905.4 16 69 0.02  0.025  0.02 0.06  0.01 15:56:17 May 09 15 min RT 2¢
TSX-V - V 100.0 0.02 · 0.025 351.0 0.025 +0.005 25.0 543.0 11 18 0.02  0.025  0.02 0.06  0.01 15:56:17   15 min
NEO ATS - U   0.02     21.0   11 0.02  0.02  0.02   15:13:32   15 min
Omega - O   0.02     41.0   11 0.02  0.02  0.02   15:13:32   15 min
CX2 - H   0.02     300.0 6 23 0.02  0.02  0.02   15:13:32   15 min
CXD - D   0.02     0.06   5        May 07   15 min
TriAct - M   0.02     0.3   1        Sep 02-20   15 min

 

Recent Trades - Last 10 of 69
Time ET Ex Price Change Volume Buyer Seller Markers
15:56:17 V 0.025 0.005 58,000 7 TD Sec 7 TD Sec K
15:56:17 V 0.025 0.005 46,000 7 TD Sec 7 TD Sec K
15:36:07 V 0.025 0.005 75,000 7 TD Sec 7 TD Sec K
15:36:07 V 0.025 0.005 42,000 7 TD Sec 7 TD Sec K
15:13:32 V 0.02   13,000 7 TD Sec 1 Anonymous K
15:13:32 U 0.02   1,000 7 TD Sec 1 Anonymous K
15:13:32 O 0.02   1,000 7 TD Sec 1 Anonymous K
15:13:32 H 0.02   1,000 7 TD Sec 1 Anonymous K
15:13:32 H 0.02   5,000 7 TD Sec 1 Anonymous K
15:13:32 V 0.02   24,000 7 TD S

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities